Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3985297 in Healthy Participants
NCT06395012Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3985297 (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants with one or more Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs). Started Jun 2024; status: completed.
02
Drugs
LY3985297
Beyond the preview
Go deeper on NCT06395012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395012.